Tesi sul tema "Thrombotic complications"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Vedi i top-19 saggi (tesi di laurea o di dottorato) per l'attività di ricerca sul tema "Thrombotic complications".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Vedi le tesi di molte aree scientifiche e compila una bibliografia corretta.
Tardy-Poncet, Brigitte. "Potential roles of TFPI in both thrombotic and hemorrhagic diseases". Thesis, Saint-Etienne, 2012. http://www.theses.fr/2012STET007T/document.
TFPI is a multivalent Kunitz-type proteinase inhibitor that directly inhibits FXa and produces FXa-dependent feedback inhibition of the FVIIa–TF complex. It was recently demonstrated that Protein S (PS) plays the role of TFPI cofactor by enhancing the TFPI inhibition of factor Xa in vivo. Approximately 80% of plasma TFPI circulates as a complex with plasma lipoproteins, about 5–20% circulating as free TFPI. Under quiescent conditions, approximately 50–80% of intravascular TFPI is stored in association with the endothelium. Full-length TFPI α carried in platelets constitutes 8-10% of the total amount of TFPI in the blood, corresponding to a quantity comparable to that of soluble full-length TFPI α in the plasma. We searched for resistance to TFPI activity in patients who presented idiopathic venous thrombosis at a young age. Plasma sensitivity to TFPI was evaluated on the basis of diluted prothrombin time (dPT) measured in patients and in control plasma in the presence (W) and absence (Wo) of exogenous TFPI. At the same time, dPT was measured on a reference plasma to establish a normalized ratio termed TFPI NR and defined as (dPT wTFPI/ dPT Wo TFPI) patient or control / (dPT wTFPI/ dPT Wo TFPI) reference plasma. In an initial study, we found that TFPI resistance could be considered as a new coagulation abnormality that could be related to unexplained thrombosis. In a second study, we failed to demonstrate a role of TFPI resistance in patients with venous thrombosis, abnormal TFPI NR being more likely related to the non-respect of preanalytical conditions rather than to an inherited trait. However, in another study, we showed that inherited or acquired PS deficiency was responsible for a TFPI resistance, providing an ex vivo demonstration that PS is the cofactor of TFPI activity. We showed that this TFPI resistance existed throughout pregnancy and that it disappeared when PS returned to normal values after delivery. We evaluated this TFPI resistance as a possible marker of the risk of a gestational vascular complication (GVC) in 72 patients at risk of developing a GVC. TFPI NR did not differ between GVC+ patients (n =15) and GVC– patients (n = 57). High levels of Lipoprotein(a) (Lp(a) have been shown to be an independent risk factor for cardiovascular disease, lowering of these levels not being achievable by any treatment except possibly aspirin. An in vitro study showed that TFPI activity could be inhibited by Lp(a). We did not confirm this TFPI inhibition in vivo in 20 obese patients with coronary insufficiency who had either normal Lp(a) levels (≤ 0.3 g/L; n = 15) or high Lp(a) levels (≥ 0.3 g/L; n = 5) . Moreover, we found no effect of aspirin treatment on Lp(a) whatever the initial level of Lp(a). Haemophilia B patients bleed less than haemophilia A patients. We showed that this difference in bleeding profile could be explained by lower free TFPI levels in haemophilia B patients compared to haemophilia A patients. In an ongoing study, we showed that in haemophilia A patients there was a strong correlation between the different parameters of thrombin generation (TG) and free TFPI. We also showed, in a TG assay performed in platelet-rich plasma (PRP) with a low TF concentration, that LT was sensitive to free TFPI levels whatever the type of haemophilia and whatever theseverity of the disease. We demonstrated that blocking TFPI by an anti-TFPI Antibody (Ab) allows complete correction of the TG profile in PRP. We showed that it is of major importance to perform a TG assay in PRP in order to evaluate the efficacy of anti-TFPI Ab in correcting TG parameters in haemophilia patients
Moussa, Mouhamed Djahoum. "Déterminants cliniques, physiopathologiques et pronostics associés aux complications liées à l’hémostase au cours des assistances circulatoires de courte durée à pompe centrifuge". Electronic Thesis or Diss., Université de Lille (2022-....), 2022. http://www.theses.fr/2022ULILS055.
The purpose of this dissertation is to characterize hemostasis-related complications in patients supported by peripheral VA-ECMO to improve their prevention and to optimize the antithrombotic therapeutic approaches in use. In a first study, we qualitatively and quantitatively described the composition of thrombi collected from the VA-ECMO circuits. We observed that these thrombi are mainly made of VWF, fibrin and in a lesser proportion of platelets and RBCs. Our quantitative approach also allowed us to demonstrate the presence of NETs while there was no active septic, confirming the possibility of aseptic NETosis under VA-ECMO. By hierarchical cluster analysis, we identified 2 types of thrombi, each of which may be related to a different mechanism of formation. In this study, the location of thrombi on the VA-ECMO circuit did not impact their compositions, highlighting the heterogeneity of thrombi formed within VA-ECMO and the multifactorial mechanisms that support thrombosis in this setting. In a second study, we compared the performance of surface coatings on VA-ECMO circuits to reduce thrombinoformation and its clinical consequences. Two of the most used coatings in daily practice were compared: the phosphorylcholin-based coating and the polysaccharide-albumin-based coating. We observed a higher rate of thrombotic complications in the phosphorylcholin group without any excess bleeding events or mortality in either group. In addition, compared with thrombi from phosphorylcholin-coated circuit junctions, those from polysaccharide-albumin-coated circuits were poorer in VWF. Our work suggests that the level of anticoagulation should be modulated according to the type of coating of the ECMO circuit.The aim of our third study was to identify the most relevant bleeding events that may guide clinical decision-making for more aggressive clinical management and a greater investment in research. To this end, we compared the association between 3 bleeding classifications with 28-day mortality. The ELSO definition already in use and the BARC classification classes ≥ type 2 were associated with 28-day mortality and thus retained as definitions of major bleeding. Laboratory parameters that are predictors major bleeding according to the ELSO definition were decreased fibrinogen, platelet count, and hemoglobin at cannulations. Body mass index and postcardiotomy etiology were also predictive of ELSO major bleeding. In an additional work related to the topic of the thesis, we studied two of the most used laboratory tests for the monitoring of systemic heparin during VA-ECMO, the APTT and the Anti-Xa activity, to identify the most relevant. First, we studied the relationship between these two tests and then analyzed in a second objective the impact of biological influencing factors on this relationship. Next, we determined their associations with thrombotic and hemorrhagic complications. Although linearly associated, the rate of discordance between their measurements was 39 % for an Anti-Xa reference range of 0.3 - 0.7 IU/mL. Neither APTT nor Anti-Xa was associated with thrombotic or bleeding complications. Taken together, our results highlight the heterogeneity of thrombi from peripheral VA-ECMO, the involvement of numerous causal factors that underline thrombotic and hemorrhagic complications, both not predictable by routine tests. Finally, our work underscored the need for new approaches in thrombotic or hemorrhagic complications management with targets set at an individual level considering both patient and ECMO circuit characteristics
Lapidus, Lasse. "Thromboembolism following orthopaedic surgery : outcome and diagnostic procedures after prophylaxis in lower limb injuries /". Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-111-1/.
Smith, Sarah Faith. "Influences on the incidence of clinical deep vein thrombosis and pulmonary embolism in a prospectively collated population of 21,000 neurosurgical inpatients". Thesis, The University of Sydney, 2001. http://hdl.handle.net/2123/818.
Smith, Sarah Faith. "Influences on the incidence of clinical deep vein thrombosis and pulmonary embolism in a prospectively collated population of 21,000 neurosurgical inpatients". University of Sydney. Public Health and Community Medicine, 2001. http://hdl.handle.net/2123/818.
Ziaziaris, William Andrew. "Pediatric Liver Transplantation: Improvement in Outcomes". Thesis, The University of Sydney, 2016. http://hdl.handle.net/2123/16265.
Matielo, Marcelo Fernando. "Incidência de trombose venosa profunda pós-operatória no membro amputado de pacientes com doença arterial oclusiva periférica". Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/5/5132/tde-29012009-165529/.
Introduction: Patients undergoing amputation of the lower limb due to Peripheral Arterial Disease (PAD) are at risk for developing Deep Venous Thrombosis (DVT). There are few studies in the research literature on the incidence of DVT during the early postoperative period and the risk factors for the development of DVT in the amputation stump. Objective: The goal of this prospective study was to evaluate the incidence of deep venous thrombosis during the first 35 postoperative days in patients who had undergone amputation of the lower extremity due to PAD, and its relation to comorbidities and death. Method: From September 2004 to March 2006, fifty-six patients (29 men, mean age 67.25 years) underwent 62 amputations (36 below knee amputation BKA and 26 above knee amputation- AKA), and echo- Doppler scanning on preoperative, and approximately the seventh and 31st postoperative days. Results: DVT occurred in 16 (25.8%) of the amputated extremities, (10 AKA and 06 BKA). The cumulative incidence in the 35 day postoperative period was 28% (Kaplan-Meier). There was a significant difference in the incidence of DVT between AKA (37.5%) and BKA (21.2%), p = .04. Another DVT risk factor was age equal to or above 70 years (48.9 vs. 16.8%, p= .021). There was one case of symptomatic non-fatal pulmonary embolism in a patient already diagnosed with DVT. There was no relation between other comorbidities and DVT. Venous Thrombosis in the amputation stump did not influence the mortality rate which was 9.7%. Conclusions: The incidence of DVT in the early post-operative period (up to 35 days) was elevated mainly in patients 70 years of age or older and in AKA. Patients with PAD who have recently undergone major amputations should be considered at high risk for DVT, even after hospital discharge.
Oliveira, Samantha Carlos de. "Trombocitopenia induzida por heparina: aspectos clínicos e laboratoriais". Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/5/5146/tde-04112008-155406/.
Heparin induced thrombocytopenia (HIT) is an immune-hematologic syndrome mediated by a heparin dependent antibody that causes platelet activation, platelet aggregation, and can be associated with thrombosis and death. HIT occurs in about 1-5% of patients receiving heparin therapy up to 5 days or more. Many factors influence on the frequency of HIT. This is a pioneer Brazilian study to determine the frequency of HIT on patients under heparin therapy, and the relationship of HIT with gender, heparin type and the FcRIIa platelet receptor genotype. 278 patients from the Intensive Care Unit and Cardiac Care Unit at InCor-HCFMUSP treated with Unfractionated Heparin (UFH) and/or Low Molecular Weight Heparin (LMWH) for 5 or more days were studied. Known causes of thrombocytopenia were excluded. Platelet count was monitored pre and post heparin therapy. All selected patients were tested for detection of anti-heparin/PF4 antibody (ID-PaGIA, DiaMed; and Asserachrom®-HPIA, Stago). HIT frequency found was 6 (2,2%) and the frequency of thrombocytopenia (determined by a decrease in the platelet count below 50%, after the introduction of heparin therapy) and positive anti-heparin/PF4 antibody test was 24,3%. Patients gender was not related to TIH, neither to thrombocytopenia nor to the presence of antiheparin/ PF4 antibody. Thrombosis events were more frequent in women than in men. Thrombocytopenia, related to the type of heparin, was more frequent in patients that had used both types of heparin and less frequent in those that used only LMWH. FcRIIa platelet receptor genotype was associated with neither HIT nor with gender. This study has provided the frequency of HIT in a Brazilian patient population under heparin therapy and auxiliary in the HIT diagnosis. The ID-PaGIA (DiaMed) was shown to be the best test to correlate the presence of anti-heparin/PF4 antibody to thrombocytopenia and thrombosis event. The use of both heparin types promotes more thrombocytopenia. New studies are needed to confirm the relationship between heparin type and thrombocytopenia with HIT
Nilsson, Elin, e Linnéa Oskarsson. "Graderade kompressionsstrumpors preventiva effekt för djup ventrombos och posttrombotiskt syndrom". Thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-408302.
ABSTRACT Background: Deep vein thrombosis (DVT) is a serious complication postoperatively and can lead to a life threatening condition for the patient. Graded compression stockings (GCS) are used in many post-operative departments along with other prophylactic measures to prevent the development of DVT. Compression stockings are also used to prevent postthrombotic syndrome (PTS) after a DVT. PTS can develop because the venous valves are damaged by a DVT, as a result, the blood is stored and edema is formed, which leads to poor nutritional and oxygen supply to the tissues. Aim: The aim of the literature study was to investigate whether compression stockings had any effect in preventing DVT postoperatively, and also whether the compression stockings had any effect in preventing PTS after a DVT. Method: Literature study based on 11 RCT studies. Results: GCS without other prophylactic measures was found to have a good effect in avoiding the development of DVT in patients who underwent surgery. However, the use of GCS in combination with other proven prophylaxis was found to have no significant effect in further reducing the onset of DVT. The results regarding the GCS effect to avoid the development of PTS showed no unambiguity. Conclusion: GCS has a preventive effect to avoid the onset of DVT. However, the use of GCS in combination with other prophylaxis does not potentiate the effect of prevention for DVT. The effect of GCS in preventing the onset of PTS is not unambiguous and several studies are needed to see evidence of this.
Galanaud, Jean-Philippe. "Les thromboses veineuses méconnues des membres inferieurs : thromboses veineuses profondes distales et thromboses veineuses superficielles". Thesis, Montpellier 1, 2011. http://www.theses.fr/2011MON1T027.
Background: Though they represent the majority of all lower limbs thromboses, isolated distal deep-vein thrombosis (DVT) (without symptomatic pulmonary embolism (PE)) and isolated superficial vein thrombosis (SVT) (without DVT or PE) have been poorly studied. Their clinical significance and management are under debate.Methods: Data from epidemiological multicenter prospective studies OPTIMEV, POST, RIETEResults and comments: Isolated distal DVT: Distal and proximal DVTs exhibit a different risk factor profile, the latter being more associated with chronic risk factors. Three-month mortality of distal DVT patient is lower than that of proximal DVT ones but is higher than that of controls. This evidences that distal DVT is a clinically significant finding. Differences in population profile and outcomes suggests that the benefit/risk ratio of anticoagulant treatment is not similar. Data from proximal DVT clinical trials should no longer be extrapolated to distal DVT.Isolated SVT: In case of SVT the risk of concomitant DVT is high. A compression ultrasonographic exam should be performed and at least explore the whole deep venous system of the affected limb. Male gender and history of DVT/Pulmonary embolism are independent predicators of recurrence. Some SVT can be safely treated without anticoagulants. On contrary, in patients with cancer or a sapheno-femoral junction involvement, the risk of deep venous recurrence is high even upon full therapeutic dose of anticoagulants
Linden, Matthew D. "The haemostatic defect of cardiopulmonary bypass". University of Western Australia. School of Surgery and Pathology, 2003. http://theses.library.uwa.edu.au/adt-WU2006.0009.
Grebelis, Arimantas. "Pakartotinės operacijos po širdies vožtuvų protezavimo". Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2009. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2009~D_20090611_130902-56448.
The review of scientific work presented for habilitation procedure summarizes the experience of redo operations of patients after replacement of heart valves accumulated at the Heart Surgery Centre of Vilnius University Clinic of Angiology and Cardiology. The efficacy of low thrombogenicity valve prostheses was evaluated. It was found out that the mortality rate of very severely ill patients with infected did not decrease; however the larger number of patients in functional class III were being operated during the period of recent years and the results of these operations were excellent. The rate of redo tricuspid valve operations had decreased effectively because of more radical surgery treatment of this valve during the primary operation. The operation of replacement of old ball prosthesis has been validated. The new incisions of the heart were introduced as well as new methods of performance of chest box incisions and pharmacologic and non-pharmacologic methods of perioperative hemostasis; the methods mentioned above effectively reduced the risk of bleeding. The original method of the left ventricle venting via separate thoracotomy incision enabled to reduce postoperative heart failure. This work is based on the results of operations performed in cooperation with co-workers. As a chief of the department where the patients with pathology of heart valves are treated, I am performing more than a half of redo operations. The scientific presentations concerning the results of... [to full text]
Martí, Sáez Edelmira. "Trombofilia y embarazo". Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/394038.
INTRODUCTION: Thromboembolic disease is the main cause of maternal mortality in Developed countries. Gestation is an hypercoagulable state with a predisposition to thrombosis, even more if there is another risk factor as thrombophilia. Thrombophilia has also been related with other frequent complications, the so-called vascular placental complicatons (VPC), due to placental insufficiency. There is a lack of evidence in this subject because of the absence of well-designed clinical randomized trials. OBJECTIVES: This lack of evidence conducted us to the design of the TEAM Project. The main objectives were: 1. Establish the prevalence of thrombophilia in pregnancy-related thrombosis and VPC. 2. Evaluate the clinical management of these complications. 3. Determine effectiveness and security of treatments used in this scenarios. MATERIALS AND METHODS: Multicenter, multidisciplinary, prospective and observational study. We analysed 4 patient cohorts: 1. Thrombosis cohort, 2. thrombosis prophylaxis cohort, 3. VPC cohort, 4. VPC prophylaxis cohort. We developed an informatic registry for data collection. We study clinic characteristics, performance of thrombophilia screening and antithrombotic treatments used in each cohort. RESULTADOS: A total of 1032 episodes and 1000 patients were registered. Distribution of these episodes was: 57 (5.5%) thrombosis, 312 (30.2%) thrombosis prophylaxis, 368 (35.7%) VPC and 257 (24.9%) PVC prophylaxis. In the VPC groups pregnancy loss was the most frequent complication registered (65.5 and 94.2% respectively). Thrombophilia studies were made in 82.6% patients in VPC cohort and in 70.2% of thrombosis patients. Positive results were obtained in 47 and 59% of patients in thrombosis and thrombosis prophylaxis groups and in 21% of patients with VPC. In this group the most common defects found were high levels of FVIII, no-O ABO genotype, positive antiphospholipid antibodies and homocygosity for F12C46T polymorphism. Antithrombotic treatment was used in 85% of thrombosis prophylaxis episodes, mainly with low molecular weight heparins (LMWH), and in 77% of VPC prophylaxis episodes, mainly with LMWH and aspirin. Only two major hemorrhagic complications were registered. Treatment effectiveness could not be evaluated in thrombosis prophylaxis cohort because of a very low recurrence rate (0.32%). Prophylaxis with LMWH +/- aspirin was not related with a better pregnancy outcome in VPC prophylaxis group. CONCLUSIONES: Thrombophilia studies were made to most patients in this registry i all four cohorts. Results were different in patients with thrombosis and VPC. In this group we found a high prevalence of high levels of FVIII, positive antiphospholipid antibodies and homocygosity for F12C46T polymorphism. Most patients in VPC prophylaxis group with or without thrombophilia recieved LMWH +/- aspirin, but we did not find a benefit of these treatments. Further studies with more patients will be needed to confirm our findings.
Silva, Katia Regina da. "Estudo clínico randomizado para profilaxia das complicações tromboembólicas pós-implante transvenoso de dispositivos cardíacos eletrônicos em pacientes de alto risco". Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/5/5156/tde-12092008-141236/.
Introduction: The incidence of venous thrombosis after cardiac devices implantation is high. Ventricular dysfunction and previous transvenous temporary leads ipsilaterally to the permanent implantation are independent risk factors. The effect of prophylactic strategies to prevent these complications remains controversial. The aim of this clinical, randomized and controlled study was to evaluate the role of oral anticoagulant therapy in the prevention of these complications in high risk patients, analyzing the effect on the venous obstructions incidence, the safety, effectiveness and complications of this treatment. Method: Between February 2004 and September 2007, 101 adult patients submitted to first transvenous cardiac devices implantation, with left ventricular ejection fraction <=0.40 and/or previous transvenous temporary leads were evaluated. After device implantation, patients were randomly assigned to receive either placebo or warfarin. Periodical clinical and laboratorial evaluations were performed to anticoagulant management. Following the six-month period, every patient was submitted to a digital subtraction venography. Data analysis was performed according to the \"intention-to-treat\" principle. The association of demographic, clinical and procedure variables with the presence of venous lesions was analyzed by the Chi-square, Fisher\'s exact, or \"t\" Student tests, and logistic regression model was used to identify risk factors. Results: Baseline characteristics were similar in both groups and no significant difference was observed in demographic, clinical and procedure variables. During the follow-up period, six patients died, four related to heart failure progression and two of sudden death. Four of the patients dead were allocated in Warfarin group and two in Placebo group. Only one patient of the Warfarin group presented with gastrointestinal bleeding, requiring hospitalization and blood transfusion. The median INR of patients in the Warfarin group was 2.3 ± 0.7, whereas the median INR in the Placebo group was 1.1 ± 0.3. This difference was maintained throughout the study period. The median hemoglobin and hematocrit values were similar in both groups, with 13.9 ± 1.6g / dL and 41.2 ± 4.6% in the Placebo group and 14.0 ± 1.4g / dL and 41.9 ± 3.7% in the Warfarin group. The frequency of venous obstructions in the Warfarin group was 38.6% compared with 60.4% in the Placebo group (P=0.018), corresponding to an absolute risk reduction of 22% (RR= 0.63, 95% CI= 0.013-0.42). The comparison between obstructed and non-obstructed patients showed that warfarin use was associated with a lower incidence of venous lesions (P= 0.037) and that Chagas\' disease presence was associated with a higher incidence (P= 0.051). Logistic regression analysis showed that only absence of anticoagulant therapy (P=0.038; OR=2.424, 95% CI= 1.048 - 5.606) was a predictor of venous obstruction. Conclusion: The prophylactic use of the anticoagulation therapy has been safe and reduced the frequency of venous thrombosis after transvenous cardiac devices implantation in high risk patients.
Mezouar, Soraya. "Involvement of platelets in inflammation and cancer". Thesis, Aix-Marseille, 2015. http://www.theses.fr/2015AIXM5045.
In cancers, the blood coagulation cascade and platelets can be activated to form thrombosis. This state will mainly due by the tumor and their microparticles (MPs) expression of tissue factor (TF), key protein of the coagulation cascade. In the first part of this study, we demonstrated that TF and the TF pathway inhibitor expressed by cancer MPs and the platelet P-selectin are involved in tumor progression, metastasis and the associated thrombosis in pancreatic cancer in mice. We showed the key role-play by αvβ3 and αvβ1 integrins and neutrophils extracellular traps in the interaction between cancer cells-derived MPs and platelets. We also evaluated the effect of clopidogrel, but not aspirin, treatment exhibits an anti-tumor action and limits thrombosis formation in preclinical models of pancreatic cancer. This study initiates a national investigation of a multicenter clinical phase III study to evaluate the therapeutic potential of clopidogrel in pancreatic cancer patients. In the second part of this study, we identified a “population of neutrophils expressing TF” that acts like a starter of the thrombus formation. At the reverse, in a sterile inflammatory model, our work showed the primordial role of platelet P-selectin in the slow rolling, the adhesion and the transmigration of neutrophils. All together our results suggest that the cooperation between the endothelium, platelets, MPs and neutrophils constitute essential mechanisms acting in the thrombosis and the inflammation
小林, 真一郎, e Shin-ichiro Kobayashi. "Increased von Willebrand Factor to ADAMTS13 Ratio as a Predictor of Thrombotic Complications Following a Major Hepatectomy". Thesis, 2014. http://hdl.handle.net/2237/20419.
Dandachli, Mourad. "L’efficacité du CD154 monomérique dans le traitement des complications thrombotiques". Thèse, 2016. http://hdl.handle.net/1866/19251.
CD154 has emerged as an important player in the pathogenesis of several autoimmune diseases, as well as vascular dysfunctions. CD154 is a member of the tumour necrosis factor family of pivotal importance in humoral immunity. However, CD154 also shares critical inflammatory functions through its interaction with its classical CD40 receptor or recently identified binding partners, namely αIIbβ3, α5β1 and αMβ2. These responses imply CD154 as a key factor in chronic inflammatory disorders including autoimmune diseases and thrombosis. Disrupting the interaction of CD154 with its receptors through anti-CD154 Abs significantly inhibits the development of these diseases, albeit serious side effects have been associated with these therapies. To overcome these adverse effects, other approaches such as knockout, antisense oligonucleotide and siRNA targeting were developed. These approaches were focused on the CD154/CD40 interaction and did not address the interaction of CD154 with its other receptors. Thus, there is a need for novel CD154 treatments for the prevention/abrogation of inflammatory or autoimmune diseases that address all CD154 receptors. Our group profoundly investigated the structural/functional interaction of CD154 with its various receptors. Given the importance of the trimeric structure of CD154 for its biological activity, we generated monomeric form of the molecule that can specifically bind to one receptor without inducing intracellular activation. This agent represents a potential therapeutic tool for the treatment of CD154-mediated diseases such as thrombotic events.
Washburn, Ashley E. "Hemostatic adaptions following exercise training in patients with cancer". 2012. http://liblink.bsu.edu/uhtbin/catkey/1671230.
School of Physical Education, Sport, and Exercise Science
Bassa, Fatima Cassim. "Coagulation system abnormalities in human immunodeficiency virus (HIV) positive African (Black) patients with acute upper segment deep vein thrombosis(DVT) of the lower limbs". Thesis, 2006. http://hdl.handle.net/10413/573.
Thesis (MMed)-University of KwaZulu-Natal, Durban, 2006.